Imugene Limited (AU:IMU) has released an update.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Imugene Limited has launched the first Australian site for its azer-cel Phase 1b clinical trial at the Royal Prince Alfred Hospital in Sydney, aiming to provide a new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This off-the-shelf CAR T-cell therapy uses donor T-cells, allowing for quicker treatment compared to traditional methods. Early results from U.S. trials have shown promising responses, offering hope to those with limited treatment options.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
